The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa
Open accessAbstract
BACKGROUND: The efficacy and toxic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) are uncertain when these agents are used with a protease inhibitor in second-line therapy for human immunodeficiency virus (HIV) infection in resource-limited settings. Removing the NRTIs or replacing them with raltegravir may provide a benefit. METHODS: In this open-label trial in sub-Saharan Africa, we randomly assigned 1277 adults and adolescents with HIV infection and first-line treatment failure to receive a ritonavir-boosted protease inhibitor (lopinavir-ritonavir) plus clinician-selected NRTIs (NRTI group, 426 patients), a protease inhibitor plus raltegravir in a superiority comparison (raltegravir group, 433 patients), or protease-inhibitor monotherapy after 12 weeks of induction therapy with raltegravir in a noninferiority comparison (monotherapy group, 418 patients). The primary composite end point, good HIV disease control, was defined as survival with no new World Health Organization stage 4 events, a CD4+ count of more than 250 cells per cubic millimeter, and a viral load of less than 10,000 copies per milliliter or 10,000 copies or more with no protease resistance mutations at week 96 and was analyzed with the use of imputation of data (≤4%). RESULTS: Good HIV disease control was achieved in 60% of the patients (mean, 255 patients) in the NRTI group, 64% of the patients (mean, 277) in the raltegravir group (P=0.21 for the comparison with the NRTI group; superiority of raltegravir not shown), and 55% of the patients (mean, 232) in the monotherapy group (noninferiority of monotherapy not shown, based on a 10-percentage-point margin). There was no significant difference in rates of grade 3 or 4 adverse events among the three groups (P=0.82). The viral load was less than 400 copies per milliliter in 86% of patients in the NRTI group, 86% in the raltegravir group (P=0.97), and 61% in the monotherapy group (P<0.001). CONCLUSIONS: When given with a protease inhibitor in second-line therapy, NRTIs retained substantial virologic activity without evidence of increased toxicity, and there was no advantage to replacing them with raltegravir. Virologic control was inferior with protease-inhibitor monotherapy. (Funded by European and Developing Countries Clinical Trials Partnership and others; EARNEST Current Controlled Trials number, ISRCTN37737787, and ClinicalTrials.gov number, NCT00988039.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple imputation of discrete and continuous data by fully conditional specification
van Buuren, S. (2007) · Statistical Methods in Medical Research · doi:10.1177/0962280206074463 · Cited by 2,827
Cited by
HIV protease inhibitors: a review of molecular selectivity and toxicity
Wang, Y., Lv, Z., & Chu, Y. (2015) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s79956 · Cited by 450
HIV-1 drug resistance and resistance testing
Clutter, D. S., Jordan, M. R., Bertagnolio, S., & Shafer, R. W. (2016) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2016.08.031 · Cited by 333
Ageing and inflammation in patients with HIV infection
Nasi, M., De Biasi, S., Gibellini, L., Bianchini, E., Pecorini, S., Bacca, V, Guaraldi, G., Mussini, C., Pinti, M., & Cossarizza, A. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12814 · Cited by 277
Formulation and pharmacology of long-acting rilpivirine
Williams, P. E., Crauwels, H. M., & Basstanie, E. D. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000164 · Cited by 86
Metadata
- Authors
- Paton, N. I., Kityo, C., Hoppe, A., Reid, A., Kambugu, A., Lugemwa, A., van Oosterhout, J. J., Kiconco, M., Siika, A., Mwebaze, R., Abwola, M., Abongomera, G., Mweemba, A., Alima, H., Atwongyeire, D., Nyirenda, R., Boles, J., Thompson, J., Tumukunde, D., Chidziva, E., Mambule, I., Arribas, J. R., Easterbrook, P. J., Hakim, J., Walker, A. S., & Mugyenyi, P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 234-247
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125756020
- Cited by
- 202
- References
- 1
- FWCI
- 20.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa. https://app.cochat.ai/papers/10.1056/nejmoa1311274
- The paper
- Paton, N. I., Kityo, C., Hoppe, A., Reid, A., Kambugu, A., Lugemwa, A., van Oosterhout, J. J., Kiconco, M., Siika, A., Mwebaze, R., Abwola, M., Abongomera, G., Mweemba, A., Alima, H., Atwongyeire, D., Nyirenda, R., Boles, J., Thompson, J., Tumukunde, D., . . . Mugyenyi, P. (2014). Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1311274
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.